Syndax Pharmaceuticals Inc.
400 Totten Pond Road
180 articles with Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced five poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago, Illinois.
Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update
Phase 2 ENCORE 601 PD-(L)1 refractory melanoma cohort data and melanoma registration strategy disclosure forthcoming in 2Q18; ENCORE 601 PD-(L)1 refractory NSCLC cohort data expected 2Q18; Initial data on MSS-CRC cohort of ENCORE 601 to drive decision on advancement into second stage expected in 2Q18; Company to host conference call today at 4:30 p.m. ET
Syndax Pharmaceuticals, Inc. today announced eight presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting
Under the terms of the agreement, Syndax and Astra will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in multiple solid tumor types.
The trial will assess the efficacy, safety, and pharmacokinetics of immunotherapy combination in HR+, HER2- metastatic breast cancer.
Syndax Pharma Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
Syndax Pharma today announced results from the NSCLC and melanoma cohorts of ENCORE 601, an open-label, Phase Ib/II clinical trial employing a Simon two-stage design to evaluate the combination of entinostat plus Merck's anti-PD-1 therapy, KEYTRUDA.
Syndax Pharma Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update
As of September 30, 2017, Syndax had $120.6M in cash, cash equivalents and short-term investments.
Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017
Syndax announced today that it will release its third quarter 2017 financial results on Tuesday, November 7, 2017, after the close of the U.S. financial markets.
Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors
Syndax today announced that it has entered into an exclusive worldwide license agreement with Vitae Pharma for a portfolio of preclinical, orally-available small molecule inhibitors of the interaction of Menin with the MLL protein.
Syndax today announced that it has agreed to sell 2,021,018 shares of its common stock to BVF in a registered direct offering.
Syndax Announces Dosing Of First Patient In Pivotal Trial Of Entinostat For The Treatment Of Advanced Or Recurrent Breast Cancer In Japan By Partner Kyowa Hakko Kirin
Syndax To Announce Second Quarter 2017 Financial Results And Host Conference Call And Webcast On August 10, 2017
Syndax Release: Preclinical Results Support Entinostat's Role In Targeting The Tumor Microenvironment To Enhance Immune Checkpoint Therapy
Syndax Announces Results From Phase II ENCORE 601 Trial Of Entinostat In Combination With KEYTRUDA (Pembrolizumab) For The Treatment Of Advanced Melanoma
Syndax Announces Advancement Of ENCORE 601 In Non-Small Cell Lung Cancer Patients With Disease Progression On Or After PD-1 Therapies